tafluprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| prostaglandins | 4229 | 209860-87-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 10, 2012 | FDA | OAK PHARMS INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ocular hyperaemia | 227.61 | 37.09 | 56 | 871 | 25088 | 63463007 |
| Eye irritation | 159.10 | 37.09 | 41 | 886 | 21930 | 63466165 |
| Eye pain | 146.01 | 37.09 | 42 | 885 | 33812 | 63454283 |
| Eye pruritus | 116.53 | 37.09 | 31 | 896 | 18640 | 63469455 |
| Eye swelling | 61.51 | 37.09 | 20 | 907 | 23898 | 63464197 |
| Intraocular pressure increased | 42.17 | 37.09 | 11 | 916 | 6067 | 63482028 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ocular hyperaemia | 87.01 | 57.93 | 21 | 366 | 11431 | 34945113 |
| Eye irritation | 68.46 | 57.93 | 16 | 371 | 7545 | 34948999 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ocular hyperaemia | 152.53 | 32.39 | 41 | 1022 | 28165 | 79715160 |
| Eye pain | 89.59 | 32.39 | 29 | 1034 | 37549 | 79705776 |
| Eye irritation | 70.47 | 32.39 | 21 | 1042 | 20660 | 79722665 |
| Eye pruritus | 57.74 | 32.39 | 18 | 1045 | 20552 | 79722773 |
| Pemphigoid | 41.28 | 32.39 | 13 | 1050 | 15302 | 79728023 |
| Atrioventricular block second degree | 41.14 | 32.39 | 11 | 1052 | 7301 | 79736024 |
| Cardiovascular insufficiency | 34.51 | 32.39 | 8 | 1055 | 2973 | 79740352 |
| Intraocular pressure increased | 34.17 | 32.39 | 10 | 1053 | 9195 | 79734130 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | S01EE05 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Prostaglandin analogues |
| FDA CS | M0017805 | Prostaglandins |
| FDA MoA | N0000000106 | Prostaglandin Receptor Agonists |
| FDA PE | N0000009526 | Increased Prostaglandin Activity |
| FDA EPC | N0000175454 | Prostaglandin Analog |
| CHEBI has role | CHEBI:66900 | prostaglandin receptor agonists |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ocular hypertension | indication | 4210003 | DOID:9282 |
| Open-angle glaucoma | indication | 84494001 | DOID:1067 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0015% | ZIOPTAN | THEA PHARMA | N202514 | Feb. 10, 2012 | RX | SOLUTION/DROPS | OPHTHALMIC | 10864159 | May 28, 2029 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin F2-alpha receptor | GPCR | AGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4031331 | VUID |
| N0000184322 | NUI |
| D06274 | KEGG_DRUG |
| 4031331 | VANDF |
| C1451502 | UMLSCUI |
| CHEBI:66899 | CHEBI |
| CHEMBL1963683 | ChEMBL_ID |
| DB08819 | DRUGBANK_ID |
| C485333 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7451 | IUPHAR_LIGAND_ID |
| 8374 | INN_ID |
| 1O6WQ6T7G3 | UNII |
| 9868491 | PUBCHEM_CID |
| 1244607 | RXNORM |
| 187543 | MMSL |
| 26696 | MMSL |
| 013244 | NDDF |
| 699181001 | SNOMEDCT_US |
| 704470009 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Tafluprost | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-6184 | SOLUTION/ DROPS | 0.00 mg | OPHTHALMIC | ANDA | 24 sections |
| ZIOPTAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-609 | SOLUTION/ DROPS | 0.00 mg | OPHTHALMIC | NDA | 25 sections |
| ZIOPTAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-609 | SOLUTION/ DROPS | 0.00 mg | OPHTHALMIC | NDA | 25 sections |
| ZIOPTAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-609 | SOLUTION/ DROPS | 0.00 mg | OPHTHALMIC | NDA | 25 sections |
| tafluprost | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-264 | SOLUTION/ DROPS | 0.00 mg | OPHTHALMIC | ANDA | 23 sections |
| Tafluprost | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65302-062 | SOLUTION | 0.00 mg | OPHTHALMIC | ANDA | 2 sections |
| Tafluprost Ophthalmic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-429 | SOLUTION/ DROPS | 0.00 mg | OPHTHALMIC | NDA authorized generic | 25 sections |
| ZIOPTAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82584-609 | SOLUTION/ DROPS | 0.02 mg | OPHTHALMIC | NDA | 28 sections |